Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 4 of 88« First...23456...102030...Last »

Roche Halts Colorectal Cancer Trial Recruitment After Four Patient Deaths

Roche temporarily halted recruiting patients to the company’ s Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths.

Read More »

vTv Therapeutics’ Alzheimer’s Drug Fails in Phase III Trial

vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in the Phase III STEADFAST clinical trial. The new drug candidate was being evaluated in patients with mild Alzheimer’s disease.

Read More »

Researchers propose new Alzheimer’s definition based on biology

Alzheimer’s researchers proposed a radical change in the way the disease is defined, focusing on biological changes in the body rather than clinical symptoms such as memory loss and cognitive decline.

Read More »

Failed Clinical Trial: Menlo’s Stock Tanks

Menlo Therapeutics’ stock dropped 55 percent in premarket trading after the company’s serlopitant failed to meet primary and secondary endpoints in a Phase II clinical trial.

Read More »

AbbVie’s Arthritis Drug Dazzles in Phase III Trial

AbbVie announced positive top-line data from the company’s Phase III SELECT-COMPARE clinical trial of upadacitinib in moderate-to-severe rheumatoid arthritis.

Read More »

Therapix gets positive Tourette’s drug trial results

Israel’s Therapix Biosciences announced positive results from a Phase IIa trial of its cannabinoid-based drug to treat Tourette syndrome (TS), sending the company’s stock price jumping.

Read More »

Merck’s Keytruda helps lung cancer patients live longer in trial

Merck & Co.’s blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial.

Read More »

Incyte, Merck melanoma combo therapy fails study

An independent committee concluded that Inctye Corp.’s drug for a type of skin cancer in combination with Merck & Co.’s Keytruda failed to meet the main goal in a late-stage study.

Read More »

Smartphones could help measure Parkinson’s disease symptoms

An experimental smartphone application could monitor changes in Parkinson’s disease symptoms throughout the day, sending data to doctors to help them treat patients, U.S. researchers say.

Read More »

Lilly’s Cyramza succeeds in late-stage liver cancer trial

Eli Lilly and Co.’s cancer drug Cyramza helped patients with liver cancer live longer, meeting the main goal of a late-stage trial four years after failing a prior study.

Read More »

Smartphone app might offer new way to measure blood flow

An experimental smartphone app might be an effective alternative to a traditional method of assessing circulation in people who need surgery to restore normal blood flow to the heart, a small study suggests.

Read More »

Rigel’s Tavalisse Fails Kidney Disease Trial

As Rigel Pharmaceuticals awaits a regulatory decision for Tavalisse (fostamatinib) for a platelet disorder, the company reported a developmental setback for the therapy in another clinical trial.

Read More »

Researchers Develop Possible New RNA Therapy for West Nile Virus

A research group at Yale University and from Hanyang University, South Korea, developed a new RNA therapy for West Nile Virus.

Read More »

Rare heart disease drug succeeds in late-stage study

Pfizer Inc.’s experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.

Read More »

MediciNova’s Drug Flunks Phase II Trial

La Jolla, Calif.-based MediciNova announced that the company’s Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.

Read More »

AnaptysBio’s Mid-Stage Peanut Allergy Data Indicates Positive Results

Shares of AnaptysBio climbed after the company released positive interim data for its experimental peanut allergy treatment.

Read More »

Clot-Busting Stroke Medicine: Mired in Controversy

An ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain and accounts for about 87 percent of all strokes, according to the American Stroke Association. A common treatment used to break up the clots and prevent brain damage has become mired in controversy.

Read More »

Esperion’s drug clears study as add-on cholesterol treatment

Esperion Therapeutics’ experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients who were already on another treatment to lower the risk of artery-clogging heart disease.

Read More »

Ablynx Lupus Drug Fails Again in Mid-Stage Trial

Ablynx’s anti-IL-6R nanobody vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.

Read More »

ImmunoGen Reports Positive Ovarian Cancer Data

ImmunoGen released positive efficacy and tolerability data from its FORWARD II trial of mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer.

Read More »

Page 4 of 88« First...23456...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2018 Focus: Agency Profiles, Manny Awards and Annual Review


Ad Right Bottom

Main Navigation